Social Capital Suvretta Holdings Corp. III (NASDAQ:DNAC) announced this morning that its shareholders approved its combination with drug developer ProKidney at a special meeting held yesterday afternoon.
An 8-K that was also filed this morning disclosed that 22,829,769 of DNAC ordinary shares were presented for redemption, representing 91.319% of DNAC’s trust. ProKidney received total gross proceeds of approximately $597 million from the transaction, which it expects to use to fund Phase 3 study of REACT, accelerate manufacturing scale-out, and prepare for its global commercial launch to treat patients with late-stage chronic kidney disease and at high risk of kidney failure.
The approval comes just one week after DNAC adjourned its original special meeting citing that the parties needed additional time to satisfy “conditions to closing of the Business Combination with respect to approval by The Nasdaq Capital Market of a listing application” for the combined company’s shares.
The newly formed company is named ProKidney Corp. and its shares will start trading on the Nasdaq under the symbol “PROK” today, July 12, 2022.
The parties initially announced their $1.8 billion combination on January 18. Winston-Salem, North Carolina-based ProKidney has launched Phase III trials of its REACT cellular therapy which promises to slow the progression of chronic kidney disease (CKD) and potentially regenerate tissues and function.
ADVISORS
- Citigroup acted as sole financial advisor and capital markets advisor to ProKidney.
- Citigroup, Morgan Stanley, Evercore, Jefferies, and UBS acted as placement agents for a portion of the PIPE.
- BofA Securities acted as capital markets advisor to SCS.
- Wachtell, Lipton, Rosen & Katz acted as legal advisor to SCS.
- Davis Polk & Wardwell LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C acted as legal advisors to ProKidney.
- Winston & Strawn LLP is serving as legal advisor to the PIPE placement agents.
CH4 Natural Solutions (NYSE:MTNE.U) has filed for a $250 million SPAC to bring both the Riverstone sponsor team and underwriter Citigroup back to the market for 2025. The team secured notably sponsor-friendly terms for the vehicle and will not overfund its trust. In fact, along with fellow Friday filer Live Oak V (NASDAQ:LOKVU), these two...
At the SPAC of Dawn Amid a restive market, SPACs have front-loaded their business this week with three of their four votes set for today and tomorrow. One of these is a completion vote, in which Bowen (NASDAQ:BOWN) will try and secure shareholder approval for its combination with Shenzhen Qianzhi BioTechnology just after having gained...
Terms Tracker for the Week Ending January 10, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This was the first full week in January and the first non-holiday week since December 23rd. All the same, 2025 has started with a bang...
Origin Investment Corp I has filed for a $60 million SPAC to hunt for an Asian target outside of China and marks ThinkEquity’s entry into the 2025 SPAC IPO market. ThinkEquity took all of 2024 off from directly underwriting SPACs as a left lead and has not brought one all the way to IPO since...
Rarely does a group of companies go through a complete industry-defining roller coaster in a matter of weeks based on the comments of two CEOs not of their direct subsector, but that is exactly the kind of winter that quantum computing companies are having. And, despite the recent valley that followed the spike, the three...